Alpine Immune Sciences (ALPN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ALPN Stock Forecast

Alpine Immune Sciences stock forecast is as follows: an average price target of $55.00 (represents a -15.35% downside from ALPN’s last price of $64.97) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.

ALPN Price Target

The average price target for Alpine Immune Sciences (ALPN) is $55.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $44.00. This represents a potential -15.35% downside from ALPN's last price of $64.97.

ALPN Analyst Ratings

Hold

According to 5 Wall Street analysts, Alpine Immune Sciences's rating consensus is 'Hold'. The analyst rating breakdown for ALPN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 3 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Alpine Immune Sciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 11, 2024	Robert Driscoll	Wedbush	$65.00	$47.04	38.18%	0.05%
Apr 11, 2024	Michael Ulz	Morgan Stanley	$65.00	$47.04	38.18%	0.05%
Apr 09, 2024	Vamil Divan	Guggenheim	$55.00	$38.53	42.75%	-15.35%
Mar 20, 2024	Andy Chen	Wolfe Research	$46.00	$40.23	14.34%	-29.20%
Mar 19, 2024	Justin Kim	Oppenheimer	$44.00	$39.95	10.14%	-32.28%

The latest Alpine Immune Sciences stock forecast, released on Apr 11, 2024 by Robert Driscoll from Wedbush, set a price target of $65.00, which represents a 38.18% increase from the stock price at the time of the forecast ($47.04), and a 0.05% increase from ALPN last price ($64.97).

Alpine Immune Sciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	5
Avg Price Target	-	-	$55.00
Last Closing Price	$64.97	$64.97	$64.97
Upside/Downside	-100.00%	-100.00%	-15.35%

In the current month, the average price target of Alpine Immune Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Alpine Immune Sciences's last price of $64.97. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
May 16, 2024	RBC Capital	Underperform	Underperform	Hold
May 16, 2024	Wedbush	Market Perform	Market Perform	Hold
Apr 15, 2024	Cowen & Co.		Hold	Downgrade
Apr 12, 2024	Leerink Partners		Market Perform	Downgrade
Apr 09, 2024	Wedbush	Buy	Buy	Hold
Apr 09, 2024	RBC Capital	Underperform	Underperform	Hold
Apr 09, 2024	Guggenheim		Buy	Initialise
Mar 19, 2024	Wedbush	Buy	Buy	Hold
Jan 26, 2024	Wedbush	Buy	Buy	Hold
Jan 26, 2024	RBC Capital	Underperform	Underperform	Hold
Dec 22, 2023	Deutsche Bank	Buy	Buy	Hold
Dec 22, 2023	Wedbush	Buy	Buy	Hold
Oct 05, 2023	RBC Capital		Outperform	Initialise

Alpine Immune Sciences's last stock rating was published by RBC Capital on May 16, 2024. The company gave ALPN a "Underperform" rating, the same as its previous rate.

Alpine Immune Sciences Financial Forecast

Alpine Immune Sciences Revenue Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	$30.85M	-	-	$9.39M	$2.78M	-	-	$13.63M	$4.53M	-	-	$3.20M	$5.64M	-	-	$1.09M	$884.00K	-	-	-	$315.00K	-
Avg Forecast	$19.87M	$17.13M	$14.77M	$12.73M	$4.72M	$3.00M	$2.99M	$2.22M	$9.10M	$7.25M	$7.08M	$6.88M	$10.96M	$18.68M	$10.04M	$16.26M	$13.97M	$21.19M	$7.77M	$6.67M	$3.10M	$5.10M	$2.13M	$376.67K	$183.33K	$250.00K	$83.33K	$113.00K	$328.42K	$616.67K
High Forecast	$19.87M	$17.13M	$14.77M	$12.73M	$4.72M	$3.00M	$5.43M	$2.22M	$14.58M	$7.25M	$7.08M	$6.88M	$10.96M	$18.68M	$10.04M	$16.26M	$13.97M	$21.19M	$7.77M	$6.67M	$3.10M	$5.10M	$2.13M	$376.67K	$183.33K	$250.00K	$83.33K	$113.00K	$394.10K	$740.00K
Low Forecast	$19.87M	$17.13M	$14.77M	$12.73M	$4.72M	$3.00M	$1.63M	$2.22M	$2.61M	$7.25M	$7.08M	$6.88M	$10.96M	$18.68M	$10.04M	$16.26M	$13.97M	$21.19M	$7.77M	$6.67M	$3.10M	$5.10M	$2.13M	$376.67K	$183.33K	$250.00K	$83.33K	$113.00K	$262.74K	$493.33K
# Analysts	1	1	1	1	1	1	2	2	5	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	7
Surprise %	-	-	-	-	-	-	-	-	3.39%	-	-	1.36%	0.25%	-	-	0.84%	0.32%	-	-	0.48%	1.82%	-	-	2.90%	4.82%	-	-	-	0.96%	-

Alpine Immune Sciences's average Quarter revenue forecast for Mar 24 based on 2 analysts is $2.22M, with a low forecast of $2.22M, and a high forecast of $2.22M. ALPN's average Quarter revenue forecast represents a -92.80% decrease compared to the company's last Quarter revenue of $30.85M (Dec 23).

Alpine Immune Sciences EBITDA Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	2	2	5	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	7
EBITDA	-	-	-	-	-	-	-	-	$1.55M	-	-	$-13.20M	$-18.23M	-	-	$-7.22M	$-16.75M	-	-	$-10.26M	$-5.97M	-	-	$-5.28M	$-6.57M	-	-	$-12.01M	$-5.20M	$-8.86M
Avg Forecast	$-18.84M	$-16.24M	$-14.00M	$-12.07M	$-4.48M	$-2.85M	$-2.83M	$-4.32M	$-8.63M	$-6.88M	$-6.71M	$-4.62M	$-7.94M	$-17.72M	$-9.53M	$-4.94M	$-13.25M	$-20.09M	$-7.37M	$-7.70M	$-2.94M	$-4.83M	$-2.02M	$-7.19M	$-173.87K	$-237.09K	$-79.03K	$-12.21M	$-5.33M	$-4.39M
High Forecast	$-18.84M	$-16.24M	$-14.00M	$-12.07M	$-4.48M	$-2.85M	$-1.55M	$-3.46M	$-2.48M	$-6.88M	$-6.71M	$-3.70M	$-6.35M	$-17.72M	$-9.53M	$-3.95M	$-13.25M	$-20.09M	$-7.37M	$-6.16M	$-2.94M	$-4.83M	$-2.02M	$-5.75M	$-173.87K	$-237.09K	$-79.03K	$-9.77M	$-4.27M	$-3.51M
Low Forecast	$-18.84M	$-16.24M	$-14.00M	$-12.07M	$-4.48M	$-2.85M	$-5.15M	$-5.18M	$-13.83M	$-6.88M	$-6.71M	$-5.54M	$-9.53M	$-17.72M	$-9.53M	$-5.93M	$-13.25M	$-20.09M	$-7.37M	$-9.23M	$-2.94M	$-4.83M	$-2.02M	$-8.62M	$-173.87K	$-237.09K	$-79.03K	$-14.65M	$-6.40M	$-5.26M
Surprise %	-	-	-	-	-	-	-	-	-0.18%	-	-	2.86%	2.30%	-	-	1.46%	1.26%	-	-	1.33%	2.03%	-	-	0.73%	37.81%	-	-	0.98%	0.98%	2.02%

2 analysts predict ALPN's average Quarter EBITDA for Mar 24 to be $-4.32M, with a high of $-3.46M and a low of $-5.18M. This is -379.20% lower than Alpine Immune Sciences's previous annual EBITDA (Dec 23) of $1.55M.

Alpine Immune Sciences Net Income Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	2	2	5	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	7
Net Income	-	-	-	-	-	-	-	-	$5.96M	-	-	$-11.01M	$-18.86M	-	-	$-7.53M	$-15.17M	-	-	$-10.64M	$-6.34M	-	-	$-5.53M	$-6.14M	-	-	$-12.38M	$-5.31M	$-8.92M
Avg Forecast	$-30.26M	$-29.60M	$-30.89M	$-30.04M	$-25.34M	$-28.08M	$-26.25M	$-4.50M	$-21.13M	$-21.41M	$-24.01M	$-4.82M	$-7.87M	$-5.76M	$-24.01M	$-5.15M	$-18.25M	$1.28M	$-21.98M	$-7.98M	$-19.96M	$-14.89M	$-14.94M	$-7.53M	$-37.46M	$-43.54M	$-43.38M	$-12.20M	$-5.44M	$-7.13M
High Forecast	$-30.26M	$-29.60M	$-30.89M	$-30.04M	$-25.34M	$-28.08M	$-18.75M	$-3.60M	$-16.51M	$-21.41M	$-24.01M	$-3.85M	$-6.29M	$-5.76M	$-24.01M	$-4.12M	$-18.25M	$1.28M	$-21.98M	$-6.39M	$-19.96M	$-14.89M	$-14.94M	$-6.03M	$-37.46M	$-43.54M	$-43.38M	$-9.76M	$-4.35M	$-5.71M
Low Forecast	$-30.26M	$-29.60M	$-30.89M	$-30.04M	$-25.34M	$-28.08M	$-31.25M	$-5.40M	$-25.75M	$-21.41M	$-24.01M	$-5.78M	$-9.44M	$-5.76M	$-24.01M	$-6.18M	$-18.25M	$1.28M	$-21.98M	$-9.58M	$-19.96M	$-14.89M	$-14.94M	$-9.04M	$-37.46M	$-43.54M	$-43.38M	$-14.64M	$-6.53M	$-8.56M
Surprise %	-	-	-	-	-	-	-	-	-0.28%	-	-	2.29%	2.40%	-	-	1.46%	0.83%	-	-	1.33%	0.32%	-	-	0.73%	0.16%	-	-	1.01%	0.98%	1.25%

Alpine Immune Sciences's average Quarter net income forecast for Mar 24 is $-4.50M, with a range of $-5.40M to $-3.60M. ALPN's average Quarter net income forecast represents a -175.54% decrease compared to the company's last Quarter net income of $5.96M (Dec 23).

Alpine Immune Sciences SG&A Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	2	2	5	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	7
SG&A	-	-	-	-	-	-	-	-	$6.37M	-	-	$5.40M	$4.39M	-	-	$4.78M	$4.54M	-	-	$3.26M	$3.05M	-	-	$1.78M	$2.10M	-	-	$2.35M	$2.11M	$2.78M
Avg Forecast	$32.60M	$28.10M	$24.23M	$20.89M	$7.75M	$4.93M	$4.90M	$3.64M	$14.94M	$11.90M	$11.62M	$3.05M	$2.21M	$30.66M	$16.48M	$3.27M	$22.92M	$34.77M	$12.75M	$2.44M	$5.09M	$8.36M	$3.50M	$618.07K	$300.83K	$410.23K	$136.74K	$185.42K	$538.91K	$1.01M
High Forecast	$32.60M	$28.10M	$24.23M	$20.89M	$7.75M	$4.93M	$8.92M	$3.64M	$23.93M	$11.90M	$11.62M	$3.67M	$2.65M	$30.66M	$16.48M	$3.92M	$22.92M	$34.77M	$12.75M	$2.93M	$5.09M	$8.36M	$3.50M	$618.07K	$300.83K	$410.23K	$136.74K	$185.42K	$646.69K	$1.21M
Low Forecast	$32.60M	$28.10M	$24.23M	$20.89M	$7.75M	$4.93M	$2.68M	$3.64M	$4.29M	$11.90M	$11.62M	$2.44M	$1.77M	$30.66M	$16.48M	$2.61M	$22.92M	$34.77M	$12.75M	$1.95M	$5.09M	$8.36M	$3.50M	$618.07K	$300.83K	$410.23K	$136.74K	$185.42K	$431.12K	$809.51K
Surprise %	-	-	-	-	-	-	-	-	0.43%	-	-	1.77%	1.98%	-	-	1.46%	0.20%	-	-	1.33%	0.60%	-	-	2.88%	6.99%	-	-	12.65%	3.91%	2.75%

Alpine Immune Sciences's average Quarter SG&A projection for Mar 24 is $3.64M, based on 2 Wall Street analysts, with a range of $3.64M to $3.64M. The forecast indicates a -42.85% fall compared to ALPN last annual SG&A of $6.37M (Dec 23).

Alpine Immune Sciences EPS Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	2	2	5	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	7
EPS	-	-	-	-	-	-	-	-	$0.15	-	-	$-0.23	$-0.41	-	-	$-0.25	$-0.52	-	-	$-0.45	$-0.27	-	-	$-0.30	$-0.33	-	-	$-0.70	$-0.38	$-2.28
Avg Forecast	$-0.47	$-0.46	$-0.48	$-0.47	$-0.40	$-0.44	$-0.41	$-0.43	$-0.33	$-0.33	$-0.38	$-0.37	$-0.26	$-0.09	$-0.38	$-0.17	$-0.28	$0.02	$-0.34	$-0.36	$-0.31	$-0.23	$-0.23	$-0.47	$-0.58	$-0.68	$-0.68	$-0.69	$-0.40	$-1.52
High Forecast	$-0.47	$-0.46	$-0.48	$-0.47	$-0.40	$-0.44	$-0.29	$-0.43	$-0.26	$-0.33	$-0.38	$-0.37	$-0.26	$-0.09	$-0.38	$-0.17	$-0.28	$0.02	$-0.34	$-0.36	$-0.31	$-0.23	$-0.23	$-0.47	$-0.58	$-0.68	$-0.68	$-0.69	$-0.32	$-1.22
Low Forecast	$-0.47	$-0.46	$-0.48	$-0.47	$-0.40	$-0.44	$-0.49	$-0.43	$-0.40	$-0.33	$-0.38	$-0.37	$-0.26	$-0.09	$-0.38	$-0.17	$-0.28	$0.02	$-0.34	$-0.36	$-0.31	$-0.23	$-0.23	$-0.47	$-0.58	$-0.68	$-0.68	$-0.69	$-0.48	$-1.82
Surprise %	-	-	-	-	-	-	-	-	-0.45%	-	-	0.62%	1.59%	-	-	1.49%	1.82%	-	-	1.26%	0.87%	-	-	0.64%	0.56%	-	-	1.01%	0.95%	1.50%

According to 2 Wall Street analysts, Alpine Immune Sciences's projected average Quarter EPS for Mar 24 is $-0.43, with a low estimate of $-0.43 and a high estimate of $-0.43. This represents a -390.00% decrease compared to ALPN previous annual EPS of $0.15 (Dec 23).

Alpine Immune Sciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ANEB	Anebulo Pharmaceuticals	$1.31	$6.00	358.02%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
ACRV	Acrivon Therapeutics	$7.21	$22.50	212.07%	Buy
ANAB	AnaptysBio	$15.99	$49.83	211.63%	Buy
BCYC	Bicycle Therapeutics	$15.14	$43.67	188.44%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
IGMS	IGM Biosciences	$7.48	$18.67	149.60%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
ADAG	Adagene	$2.10	$5.00	138.10%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
MLTX	MoonLake Immunotherapeutics	$56.30	$100.00	77.62%	Buy

ALPN Forecast FAQ

Is Alpine Immune Sciences a good buy?

No, according to 5 Wall Street analysts, Alpine Immune Sciences (ALPN) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of ALPN's total ratings.

What is ALPN's price target?

Alpine Immune Sciences (ALPN) average price target is $55 with a range of $44 to $65, implying a -15.35% from its last price of $64.97. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Alpine Immune Sciences stock go up soon?

According to Wall Street analysts' prediction for ALPN stock, the company can go down by -15.35% (from the last price of $64.97 to the average price target of $55), up by 0.05% based on the highest stock price target, and down by -32.28% based on the lowest stock price target.

Can Alpine Immune Sciences stock reach $100?

ALPN's average twelve months analyst stock price target of $55 does not support the claim that Alpine Immune Sciences can reach $100 in the near future.

What are Alpine Immune Sciences's analysts' financial forecasts?

Alpine Immune Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $12.93M (high $15.38M, low $11.58M), average EBITDA is $-14.48M (high $-12.328M, low $-17.664M), average net income is $-84.177M (high $-75.776M, low $-90.079M), average SG&A $21.22M (high $25.24M, low $18.99M), and average EPS is $-1.679 (high $-1.562, low $-1.757). ALPN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.49M (high $64.49M, low $64.49M), average EBITDA is $-61.156M (high $-61.156M, low $-61.156M), average net income is $-121M (high $-121M, low $-121M), average SG&A $105.82M (high $105.82M, low $105.82M), and average EPS is $-1.887 (high $-1.887, low $-1.887).

Did the ALPN's actual financial results beat the analysts' financial forecasts?

Based on Alpine Immune Sciences's last annual report (Dec 2023), the company's revenue was $58.88M, beating the average analysts forecast of $30.31M by 94.22%. Apple's EBITDA was $-44.25M, beating the average prediction of $-26.844M by 64.84%. The company's net income was $-32.184M, missing the average estimation of $-71.364M by -54.90%. Apple's SG&A was $22.22M, missing the average forecast of $41.51M by -46.46%. Lastly, the company's EPS was $-0.64, missing the average prediction of $-1.409 by -54.59%. In terms of the last quarterly report (Dec 2023), Alpine Immune Sciences's revenue was $30.85M, beating the average analysts' forecast of $9.1M by 238.88%. The company's EBITDA was $1.55M, missing the average prediction of $-8.634M by -117.92%. Alpine Immune Sciences's net income was $5.96M, missing the average estimation of $-21.131M by -128.21%. The company's SG&A was $6.37M, missing the average forecast of $14.94M by -57.33%. Lastly, the company's EPS was $0.15, missing the average prediction of $-0.33 by -145.45%